Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 55.85 Million USD | 23.66% |
| 2023 | 45.57 Million USD | -2.77% |
| 2022 | 46.87 Million USD | 249.34% |
| 2021 | -31.38 Million USD | -4.57% |
| 2020 | -30.01 Million USD | -197.26% |
| 2019 | 30.86 Million USD | 42.65% |
| 2018 | 21.63 Million USD | 147.28% |
| 2017 | -45.76 Million USD | -109.34% |
| 2016 | -21.86 Million USD | 20.53% |
| 2015 | -27.5 Million USD | -618.76% |
| 2014 | -3.82 Million USD | 51.4% |
| 2013 | -7.87 Million USD | 96.19% |
| 2012 | -206.74 Million USD | 21.46% |
| 2011 | -263.22 Million USD | -721.32% |
| 2010 | -32.04 Million USD | -93.93% |
| 2009 | -16.52 Million USD | -17.26% |
| 2008 | -14.09 Million USD | -16.92% |
| 2007 | -12.05 Million USD | -53.47% |
| 2006 | -7.85 Million USD | 47.96% |
| 2005 | -15.09 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 51.38 Million USD | 14.56% |
| 2024 Q2 | 44.85 Million USD | 7.84% |
| 2024 Q1 | 41.59 Million USD | -7.98% |
| 2024 Q4 | 56.36 Million USD | 9.68% |
| 2024 FY | 55.85 Million USD | 22.56% |
| 2023 Q2 | 44.56 Million USD | 81.74% |
| 2023 Q1 | 24.52 Million USD | -47.69% |
| 2023 FY | 45.57 Million USD | -2.77% |
| 2023 Q4 | 45.2 Million USD | -31.73% |
| 2023 Q3 | 66.21 Million USD | 48.58% |
| 2022 FY | 46.87 Million USD | 249.34% |
| 2022 Q3 | 28.34 Million USD | 223.44% |
| 2022 Q4 | 46.87 Million USD | 65.39% |
| 2022 Q1 | -8.76 Million USD | 72.09% |
| 2022 Q2 | 8.76 Million USD | 200.02% |
| 2021 Q2 | 22.65 Million USD | 439.45% |
| 2021 Q1 | -6.67 Million USD | 77.76% |
| 2021 FY | -31.38 Million USD | -4.57% |
| 2021 Q4 | -31.38 Million USD | 43.92% |
| 2021 Q3 | -55.96 Million USD | -347.04% |
| 2020 Q3 | 36.06 Million USD | 169.75% |
| 2020 Q4 | -30.01 Million USD | -183.22% |
| 2020 FY | -30.01 Million USD | -197.26% |
| 2020 Q1 | 55.04 Million USD | 78.36% |
| 2020 Q2 | 13.37 Million USD | -75.71% |
| 2019 Q1 | 6.54 Million USD | -69.73% |
| 2019 Q4 | 30.86 Million USD | 220.89% |
| 2019 Q2 | -13.11 Million USD | -300.32% |
| 2019 Q3 | 9.61 Million USD | 173.32% |
| 2019 FY | 30.86 Million USD | 42.65% |
| 2018 FY | 21.63 Million USD | 147.28% |
| 2018 Q4 | 21.63 Million USD | 178.5% |
| 2018 Q3 | -27.55 Million USD | 12.35% |
| 2018 Q2 | -31.44 Million USD | 32.41% |
| 2018 Q1 | -46.51 Million USD | -1.65% |
| 2017 Q3 | -49.64 Million USD | -189.93% |
| 2017 Q1 | -16.03 Million USD | 26.64% |
| 2017 Q4 | -45.76 Million USD | 7.82% |
| 2017 Q2 | -17.12 Million USD | -6.77% |
| 2017 FY | -45.76 Million USD | -109.34% |
| 2016 Q4 | -21.86 Million USD | -103.12% |
| 2016 FY | -21.86 Million USD | 20.53% |
| 2016 Q3 | -10.76 Million USD | -27.63% |
| 2016 Q2 | -8.43 Million USD | 89.16% |
| 2016 Q1 | -77.76 Million USD | -182.7% |
| 2015 Q4 | -27.5 Million USD | -122.53% |
| 2015 Q2 | -11.43 Million USD | 92.33% |
| 2015 Q1 | -149.14 Million USD | -3797.08% |
| 2015 Q3 | 122.08 Million USD | 1167.84% |
| 2015 FY | -27.5 Million USD | -618.76% |
| 2014 Q1 | 297.98 Million USD | 3883.89% |
| 2014 Q4 | -3.82 Million USD | 97.9% |
| 2014 Q3 | -182.09 Million USD | -1436.76% |
| 2014 Q2 | -11.84 Million USD | -103.98% |
| 2014 FY | -3.82 Million USD | 51.4% |
| 2013 Q4 | -7.87 Million USD | 97.6% |
| 2013 FY | -7.87 Million USD | 96.19% |
| 2013 Q2 | -178.23 Million USD | 0.0% |
| 2013 Q3 | -328.19 Million USD | -84.14% |
| 2012 FY | -206.74 Million USD | 21.46% |
| 2012 Q4 | -206.74 Million USD | 0.0% |
| 2011 FY | -263.22 Million USD | -721.32% |
| 2010 FY | -32.04 Million USD | -93.93% |
| 2009 FY | -16.52 Million USD | -17.26% |
| 2008 FY | -14.09 Million USD | -16.92% |
| 2007 FY | -12.05 Million USD | -53.47% |
| 2006 FY | -7.85 Million USD | 47.96% |
| 2005 FY | -15.09 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 4264088.931% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -888.927% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -30.531% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 22477.316% |
| Rebus Holdings, Inc. | 305 Thousand USD | -18214.182% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 986.003% |
| Qrons Inc. | 351.42 Thousand USD | -15794.696% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -8875.174% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -28.605% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 273807.639% |
| Skye Bioscience, Inc. | -5.72 Million USD | 1076.306% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -254.363% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -1256.433% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -13800.31% |
| SQZ Biotechnologies Company | -36.23 Million USD | 254.143% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -2391.189% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -5924.493% |
| Marizyme, Inc. | 18.56 Million USD | -200.814% |
| Genus plc | 190.6 Million USD | 70.693% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -2398.321% |
| Pharming Group N.V. | 109.8 Million USD | 49.129% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -6393.326% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -4501.599% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -8114.449% |
| ContraFect Corporation | -6.02 Million USD | 1026.954% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -41387.426% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -4734.417% |
| IMV Inc. | 7.67 Million USD | -628.22% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -915.255% |
| MultiCell Technologies, Inc. | 90.04 USD | -62037055.709% |
| ONE Bio Corp. | 9.04 Million USD | -517.899% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 7710.345% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -331.471% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -3983.292% |
| Q BioMed Inc. | 4.06 Million USD | -1275.816% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -82.818% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -5443.055% |
| Biomind Labs Inc. | 711.4 Thousand USD | -7751.855% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 7.742% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -2693.762% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -336.168% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -15428.691% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -39854.69% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -281060.996% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -2436.727% |
| GB Sciences, Inc. | 1.74 Million USD | -3096.803% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 30492.765% |
| HST Global, Inc. | 96.79 Thousand USD | -57608.982% |
| CSL Limited | 10.52 Billion USD | 99.469% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -26987.124% |
| Halberd Corporation | 144.72 Thousand USD | -38497.201% |
| Enzolytics Inc. | 981.65 Thousand USD | -5590.207% |
| Agentix Corp. | 37.63 Thousand USD | -148336.807% |
| Resverlogix Corp. | 6.45 Million USD | -765.885% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 8398.792% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 102.753% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 218.817% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -689.966% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1962.244% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 731.887% |
| AVAX Technologies, Inc. | -5.9 Million USD | 1046.236% |
| Zenith Capital Corp. | 10.06 Thousand USD | -554930.356% |
| Genscript Biotech Corporation | -1.06 Billion USD | 105.263% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -27768.931% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -2241.05% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -33854.528% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 305036.429% |
| Kadimastem Ltd | -253.1 Thousand USD | 22169.464% |
| Helix BioMedix, Inc. | -2.57 Million USD | 2273.446% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -175.49% |
| BioStem Technologies, Inc. | 4.47 Million USD | -1149.063% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -27655.103% |
| LadRx Corporation | -2.03 Million USD | 2842.897% |
| Cell Source, Inc. | 9.23 Million USD | -505.052% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -8694.263% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -8694.263% |
| NovAccess Global Inc. | 2.17 Million USD | -2464.111% |
| Affymax, Inc. | -5.59 Million USD | 1098.003% |
| Itoco Inc. | 228.3 Thousand USD | -24366.505% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -40975.569% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -1026.856% |
| Mobile Lads Corp. | 484.23 Thousand USD | -11435.432% |
| CytoDyn Inc. | 20.26 Million USD | -175.68% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 8633524.266% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 602778.096% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -624.867% |
| SYBLEU INC | 473.71 Thousand USD | -11691.557% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -1153.264% |
| International Stem Cell Corporation | 2.59 Million USD | -2056.689% |
| Bioxytran, Inc. | 1.89 Million USD | -2841.59% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -89397.789% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -2461.248% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -1526.624% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -553.084% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -7129.841% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 4568.66% |
| Neutra Corp. | 52.18 Thousand USD | -106934.808% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 2344.205% |
| PureTech Health plc | -167.19 Million USD | 133.409% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 22907.852% |
| IXICO plc | -4.44 Million USD | 1356.77% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -322.56% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -1.836% |
| CSL Limited | 10.52 Billion USD | 99.469% |
| Cellectis S.A. | -43.81 Million USD | 227.475% |